Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

Milind Javle, Sameek Roychowdhury, Robin Kate Kelley, Saeed Sadeghi, Teresa Macarulla, Karl Heinz Weiss, Dirk‐Thomas Waldschmidt, Lipika Goyal, Ivan Borbath, Anthony B. El-Khoueiry, Mitesh J. Borad, Wei Peng Yong, Philip A. Philip, Michael Bitzer, S. Tanasanvimon, Li Ai, Amit Pande, Harris S. Soifer, Stacie Peacock Shepherd, Susan Moran, Andrew X. Zhu, Tanios Bekaii‐Saab, Ghassan K. Abou‐Alfa